YES - says Richard Bergström, director general of the European Federation of Pharmaceutical Industries and Associations (EFPIA), who argues that blaming the pharma patent system for hepatitis C drugs’ prices is a non-starter.
New hepatitis C treatments have been a regular feature in healthcare news of late, not least because they offer that most elusive of gifts: a cure.